A Study on the Efficacy of Different Doses of Oryz-Aspergillus Enzyme And Pancreatin Tablet in Treating Pancreatic Exocrine Insufficiency After Gastrointestinal Surgery

Inclusion Criteria: * Age between 18 and 75 years (inclusive of boundary values), regardless of gender; * History of prior gastrointestinal surgical treatment, including but not limited to: I. Post-pancreatectomy patients within 3-6 months (e.g., distal pancreatectomy, mid-pancreatectomy, total pancreatectomy, pancreatoduodenectomy); II. Post-gastrectomy patients within 2-6 months (e.g., partial gastrectomy excluding total gastrectomy); * For tumor patients, the primary tumor stage before or during surgery must be Stage I or II (AJCC 8th edition). Patients in the interval between anti-tumor treatments must have undergone a washout period exceeding 28 days to avoid interference from anti-tumor therapy on this study; * Diagnosis of pancreatic exocrine insufficiency (PEI) based on comprehensive assessment by the investigator considering medical history, symptoms, nutritional status, and pancreatic function; * Gastrointestinal Quality of Life Index (GIQLI) score ≤ 105 points; * Stable postoperative condition without systemic infection, anastomotic leak, or other severe postoperative complications; * Participants fully understand the study and voluntarily sign a written informed consent form approved by the ethics committee. Exclusion Criteria: * Known allergy to any component of micafungin pancreatic enzyme tablets; * Patients with acute pancreatitis or acute exacerbation during active phase of chronic pancreatitis, or those with known contraindications listed in the product…